Taysha Gene Therapies announces $30 mln equity raise after shares double

Taysha Gene Therapies

25/10/2022 21:38

** Taysha Gene Therapies Inc  TSHA.O  falling ~13% in
extended trading as co looks to capitalize on big pop in its
shares to raise equity
    ** TSHA shares on Tues closed up 97.4% at $2.98 after
announcing late Mon $50 mln investment by Japan's Astellas
Pharma Inc  4503.T  to acquire 15% stake to support Taysha's
adeno-associated virus (AAV) gene therapies  urn:newsml:reuters.com:*:nPn2z0LB3a
    ** Astellas to receive an exclusive option to license two of
Taysha's clinical stage programs: TSHA-102 for Rett syndrome and
TSHA-120 for GAN (Giant Axonal Neuropathy)
    ** After the bell Tues, Taysha said plans to sell $30 mln of
shares with Goldman Sachs as sole bookrunner  urn:newsml:reuters.com:*:nGNXc0BQ4v
    ** Through Mon close, TSHA shares had lost nearly 90% YTD
for market cap of roughly $60 mln, per Refinitiv data
    ** Co went public in Sept 2020 IPO at $20
 (Lance Tupper is a Reuters market analyst. The views expressed
are his own)
 ((lance.tupper@thomsonreuters.com
lance.tupper@tr.com 1-332-219-1430))